$SCOR

SCOR announces the launch of a cash tender offer and its intention to issue new subordinated notes

SCOR SE said it launched a cash tender offer to buy EUR 250m Fixed to Reset Subordinated Notes due 2047 (ISIN FR0012770063; EUR 250m outstanding) and EUR 500m Fixed to Reset Subordinated Notes due 2048 (ISIN FR0013179314; EUR 500m outstanding). The offer runs 27 May–3 June 2026. SCOR also intends to issue new Tier 2-eligible subordinated notes, with proceeds funding the tender, subject to market conditions.

Original reporting
Published May 27, 2026, 7:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 27, 2026, 8:42 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
SCOR announces the launch of a cash tender offer and its intention to issue new subordinated notes — source image
Decision brief

The 30-second read

$SCORNeutralMed
01

Why it matters

The tender is conditional on issuing new notes; proceeds are earmarked for general corporate purposes including funding the tender, which can affect perceived capital adequacy and refinancing risk during the tender window.

02

Market read

This is a near-term catalyst for SCOR’s subordinated credit curve and potentially for insurer capital-structure sentiment, driven by tender execution and new-note pricing.

03

What to watch

Priority allocation mechanics and the cap/conditionality tied to successful issuance can create volatility in which tranche trades more attractively into the tender deadline.

Relevance 9/10Timing: High—tender window runs 27 May 2026 to 3 Jun 2026; results expected shortly after expiration.

Background

SCOR is refinancing existing fixed-to-reset subordinated notes and intends to issue new Euro fixed-to-floating subordinated notes eligible as Solvency II Tier 2 capital.

Company-level read

Ticker impact

$SCORNeutralMedium confidence
Context

SCOR launched a cash tender offer for its EUR 250m 2047 notes and EUR 500m 2048 notes, funded by intended new Tier 2 capital notes.

Expected impact

Near-term: credit spreads may tighten/widen depending on tender pricing and new-note yields; equity likely reacts modestly unless issuance signals stress.

Evidence & confidence

The release is specific on tender mechanics, timing (27 May–3 Jun 2026), and use of proceeds for the buyback, but provides no coupon/yield or acceptance pricing, limiting directional certainty.

Market effects

European insurers’ Tier 2 capital management can influence peers’ funding expectations and relative credit spread moves.

Most immediate impact is in European credit markets (Luxembourg-listed notes) rather than US equities.

Limited global spillover unless the tender/new issuance affects broader reinsurance/insurance capital benchmarks.

Counterpoint

If tender terms require higher concessions or new-note pricing is unfavorable, the action could be interpreted as balance-sheet pressure rather than proactive optimization.

Key entities

  • SCOR SE

    Announced a cash tender offer for its 2047 and 2048 fixed-to-reset subordinated notes and intends to issue new Solvency II Tier 2 eligible subordinated notes.

  • 2047 Notes (due 5 June 2047)

    EUR 250,000,000 fixed-to-reset subordinated notes issued 5 June 2015; first call date 5 June 2027; currently EUR 250m outstanding.

  • 2048 Notes (due 27 May 2048)

    EUR 500,000,000 fixed-to-reset subordinated notes issued 27 May 2016; first call date 27 May 2028; currently EUR 500m outstanding.

Related articles

$SCORMed

Why is SCOR stock rallying today? By Investing.com

SCOR SE shares rose about 3.5% to 34.58 on Euronext Paris after the company reported Q2 2026 results. SCOR posted net income of EUR 171 million in Q2 and EUR 397 million for the first half, with a property and casualty combined ratio of 79.5%. Morgan Stanley named SCOR a preferred European insurance pick, citing potential capital release from Solvency II changes in Jan 2027.

$SCORMed

SCOR reports 24% drop in second quarter net income By Investing.com

SCOR SE reported Q2 net income of EUR 171 million, down 24% year over year, with insurance revenue down 5.1%. The property and casualty combined ratio improved to 79.5% on lower catastrophe losses and better attritional performance. Life and health service result was hurt by a one-off arbitration outcome. SCOR posted EUR 397 million net income in H1 2026 and expects continued competitive P&C reinsurance conditions.

$SCORMedAI 9/10

SCOR successfully places EUR 500 million subordinated notes maturing in 2056

SCOR SE said it has placed EUR 500 million fixed-to-floating rate subordinated notes maturing 5 June 2056, eligible as Solvency II Tier 2 capital. The notes pay 4.510% annually until 5 June 2036, then 3-month EURIBOR plus a margin quarterly, with possible interest deferral. Moody’s rates them A3. Proceeds will fund general purposes and a concurrent EUR 250 million tender for 2047 notes; settlement expected 5 June 2026.

$MDTMed

Jury Orders Medtronic to Pay $88 Million After Finding Surgeons Were Not Adequately Warned About a Hernia Mesh

A federal jury ordered Medtronic’s Covidien unit to pay $88 million to Larry and Tammy Patterson after finding surgeons were not adequately warned about risks of Covidien’s Symbotex hernia mesh. The Aug. 4 verdict followed a three-week trial in Massachusetts. Jurors awarded $77 million to Larry and $11 million for loss of consortium, with no punitive damages.